These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 27805418)

  • 1. Re: Cui T, Kovell RC, Terlecki RP. Is it time to abandon the digital rectal examination? Lessons from the PLCO Cancer Screening Trial and peer-reviewed literature. Curr Med Res Opin 2016;32:1-7.
    Nyitray AG; Chiao EY
    Curr Med Res Opin; 2017 Feb; 33(2):315-316. PubMed ID: 27805418
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Re-evaluating PSA Testing Rates in the PLCO Trial.
    Roobol MJ
    Eur Urol; 2016 Oct; 70(4):700-701. PubMed ID: 27495847
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Taneja SS
    J Urol; 2016 Oct; 196(4):1123-5. PubMed ID: 27628793
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Reevaluating PSA Testing Rates in the PLCO Trial.
    Albers P
    Eur Urol; 2017 Feb; 71(2):300. PubMed ID: 27823819
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic Significance of Digital Rectal Examination and Prostate Specific Antigen in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Arm.
    Halpern JA; Shoag JE; Mittal S; Oromendia C; Ballman KV; Hershman DL; Wright JD; Shih YT; Nguyen PL; Hu JC
    J Urol; 2017 Feb; 197(2):363-368. PubMed ID: 27569432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More on Reevaluating PSA Testing Rates in the PLCO Trial.
    Shoag JE; Mittal S; Hu JC
    N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732806
    [No Abstract]   [Full Text] [Related]  

  • 7. More on Reevaluating PSA Testing Rates in the PLCO Trial.
    Pinsky P; Prorok P
    N Engl J Med; 2016 Oct; 375(15):1500-1501. PubMed ID: 27732807
    [No Abstract]   [Full Text] [Related]  

  • 8. Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
    Pinsky PF; Blacka A; Kramer BS; Miller A; Prorok PC; Berg C
    Clin Trials; 2010 Aug; 7(4):303-11. PubMed ID: 20571134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lethal Prostate Cancer in the PLCO Cancer Screening Trial.
    Shoag J; Mittal S; Halpern JA; Scherr D; Hu JC; Barbieri CE
    Eur Urol; 2016 Jul; 70(1):2-5. PubMed ID: 27166670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
    Braillon A; Dubois G
    J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
    [No Abstract]   [Full Text] [Related]  

  • 11. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
    Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
    Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reevaluating PSA Testing Rates in the PLCO Trial.
    Shoag JE; Mittal S; Hu JC
    N Engl J Med; 2016 May; 374(18):1795-6. PubMed ID: 27144870
    [No Abstract]   [Full Text] [Related]  

  • 13. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 Men.
    Catalona WJ; Richie JP; Ahmann FR; Hudson MA; Scardino PT; Flanigan RC; DeKernion JB; Ratliff TL; Kavoussi LR; Dalkin BL; Waters WB; MacFarlane MT; Southwick PC
    J Urol; 2017 Feb; 197(2S):S200-S207. PubMed ID: 28012755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
    Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
    J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital rectal examination for prostate cancer screening performed with colonoscopy for colon cancer screening: 2 for the price of 1.
    Fang JC; Faerber G; Samadder J
    Gastrointest Endosc; 2017 Dec; 86(6):1147-1150. PubMed ID: 28739176
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prostate cancer screening: Reasons of controversy].
    Delporte G; Villers A; Penel N
    Bull Cancer; 2018 Dec; 105(12):1111-1118. PubMed ID: 30458966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline of guidelines: prostate cancer screening.
    Loeb S
    BJU Int; 2014 Sep; 114(3):323-5. PubMed ID: 24981126
    [No Abstract]   [Full Text] [Related]  

  • 19. Digital rectal examination is a barrier to population-based prostate cancer screening.
    Philip J; Dutta Roy S; Viswanathan P
    Urology; 2006 Mar; 67(3):655; author reply 655-6. PubMed ID: 16527599
    [No Abstract]   [Full Text] [Related]  

  • 20. Digital rectal examination can detect early prostate cancer.
    Roobol MJ
    Evid Based Med; 2015 Jun; 20(3):119. PubMed ID: 25758963
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.